--- title: "CJC-1295 Dosage Guide [2026] | BodyHackGuide" url: https://www.bodyhackguide.co/guides/dosage/cjc-1295 description: "Complete CJC-1295 (Mod GRF 1-29) dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Growth Hormone / IGF-1 Axis Phase 2 (clinical development discontinued) # CJC-1295 (Mod GRF 1-29) Dosage Guide: Protocols, Calculator & Safety Everything you need to know about CJC-1295 (Mod GRF 1-29) dosing: protocols, safety, and where to buy. Dose Range Without DAC: 100-300 mcg subcutaneous 1-3x daily (typically pre-bedtime); With DAC: 1000-2000 mcg subcutaneous once weekly Frequency 1–3 times daily, typically before bed and/or upon waking Cycle Length 8–16 weeks; can be used long-term with periodic breaks Half-Life ~30 minutes (without DAC / MOD-GRF 1-29); ~6-8 days (with DAC, due to covalent albumin binding) ## Administration Routes Subcutaneous ### Quick Reconstitution Calculator Calculate syringe units instantly Syringe Draw 10.0 units 2500 mcg/ml · 0.100 ml draw Full Tool (https://www.bodyhackguide.co/tools/reconstitution) For laboratory research use only. This tool performs reconstitution math (concentration and syringe-unit conversion) and is not dosing guidance for humans or animals. ## Dosing Protocols Beginner **Entry protocol — first MOD-GRF 1-29 cycle** Goal: Establish tolerance, detect side effects, track subjective effect, confirm sourcing. **Prerequisites** 1. Baseline IGF-1 (target: mid-normal range for your age; if already high-normal, reconsider) 2. Baseline fasting glucose and HbA1c 3. Age-appropriate cancer screening up to date 4. Vendor COA confirming ≥98% purity, correct sequence, endotoxin <1 EU/mg 5. Bacteriostatic water 0.9% benzyl alcohol (not sterile water) 6. Insulin syringes 29-31G × 1/2" × 0.5 mL **Reconstitution (typical 2 mg vial)** - Add 2 mL BAC → 1 mg/mL = 1000 mcg/mL - On U-100 insulin syringe: **10 units = 0.1 mL = 100 mcg** (target dose) - See Reconstitution Tool (https://www.bodyhackguide.co/tools/reconstitution/cjc-1295) for vial-specific math **Cycle 1 — 12 weeks** **Weeks 1-2: tolerance** - **100 mcg MOD-GRF 1-29 SC, pre-bed, daily** (fasted, 2+ hours after dinner) - No stack yet — isolate tolerance - Track: injection-site reaction, flushing, sleep quality, energy, any numbness/tingling **Weeks 3-12: add ipamorelin** - **100 mcg MOD-GRF 1-29 + 200 mcg ipamorelin** — single combined injection, pre-bed - Or dose twice daily: AM fasted + pre-bed (same doses each) - Track: body composition (tape measure or DEXA), sleep architecture, recovery from training **What to expect** - **Week 1-2:** Mild flushing, possible vivid dreams, may feel more rested in AM - **Week 3-6:** Improved sleep depth, better recovery from training, possible modest fat loss - **Week 7-12:** Body composition changes (tape/DEXA if tracked), sustained energy improvement - **If nothing:** Re-examine sourcing (COA), reconstitution technique, or meal timing (postprandial blunting) **Labs at 12 weeks** - IGF-1 (target: upper-normal for age, not supraphysiologic) - Fasting glucose, HbA1c - Comprehensive metabolic panel **Decision at 12 weeks** - IGF-1 in range + benefit + no side effects → continue - IGF-1 >upper normal → reduce dose or frequency - Persistent side effects → reduce dose or stop - No benefit → stop and re-evaluate (or switch to DAC variant for trial) **Red flags — stop** - Persistent numbness/tingling (carpal tunnel signal) - Fasting glucose rising above 100 mg/dL - New joint swelling or pain - Any new palpable lump or lymphadenopathy Standard **Intermediate protocol — month 3-12** Assumes successful first cycle, no adverse events, baseline IGF-1 appropriately risen, consistent benefit. **Standard maintenance** - **MOD-GRF 1-29 100 mcg + Ipamorelin 200 mcg** combined SC - **Twice daily:** AM fasted + pre-bed - Fasted state (2+ hours post-meal) for both doses - Consistent timing day-to-day **Advanced dosing** (if benefit plateaus and IGF-1 remains in range) - Add third daily dose: pre-workout (30-60 min before training, fasted) - Stay at 100 mcg MOD-GRF per dose — do NOT escalate single-dose above 100 mcg (no additional GH pulse, just more side effects) - Ipamorelin ceiling: 300 mcg per dose (above this, cross-desensitization of ghrelin receptor) **Pairing additions** - **BPC-157 250 mcg BID SC** for tendon/joint recovery if training hard - **Creatine 5 g/day** oral (independent anabolic) - **Vitamin D3 5000 IU + K2 MK-7 100 mcg** - **Magnesium glycinate 400 mg pre-bed** (synergistic sleep) - **Protein 1.6-2.2 g/kg/day** (substrate for GH-mediated protein synthesis) **Monitoring cadence** - IGF-1 quarterly for first year, then biannually - Fasting glucose and HbA1c quarterly - CMP biannually - Symptom diary (monthly self-check for carpal tunnel, edema, joint stiffness) - Body composition (DEXA or tape) every 3-6 months **Dose adjustments** - IGF-1 too high (>upper normal for age) → reduce to once-daily or reduce per-dose to 75 mcg - Glucose rising → reduce dose, increase cardio, evaluate diet - Persistent side effects → reduce dose 25%, reassess in 4 weeks **Cycling considerations** - Continuous daily use is reasonable for 6-12 months with monitoring - Some clinicians prefer 5-days-on / 2-days-off to preserve pulsatile nature - 4-6 weeks off annually is a conservative cycle **When to pause or stop** - Any new malignancy diagnosis → stop immediately - New diabetic retinopathy → stop - Pregnancy desire (for women) → stop 3 months before attempting conception - Unexplained elevated IGF-1 beyond age-appropriate upper limit Advanced **Advanced protocol — established users, longitudinal optimization** Assumes 12+ months of uneventful use, consistent IGF-1 monitoring, documented benefit. **Dose and frequency** - MOD-GRF 1-29 100 mcg + Ipamorelin 200-300 mcg - 2-3x daily (AM fasted, optional pre-workout, pre-bed) - Consistent timing and injection technique **Precision tuning** - **Target IGF-1:** 75th percentile for age — high-normal, not above - Escalate/de-escalate by 25% dose steps at 8-week intervals based on IGF-1 + subjective response - Do not exceed 400 mcg total MOD-GRF 1-29 daily (dose-response flattens; side effects accumulate) **Rotational strategies** - 12 weeks on / 4 weeks off quarterly to preserve somatotroph sensitivity - Or 6 months on / 1 month off biannually - Re-titrate after breaks **Comprehensive stack example** - AM fasted: MOD-GRF 100 mcg + Ipamorelin 200 mcg SC - Pre-workout: same - Pre-bed: same - BPC-157 250 mcg BID - TB-500 2 mg weekly (sports injury support) - NAD+ precursor 500 mg daily - Testosterone replacement (if clinically indicated and supervised) - Vitamin D, K2, magnesium, omega-3s, creatine **Advanced monitoring** - IGF-1 and IGFBP-3 quarterly - Fasting insulin, HOMA-IR annually - hs-CRP, IL-6 annually - Comprehensive cancer screening per age (colonoscopy, mammography/prostate, skin) - Echocardiogram every 2-3 years if continuous use >3 years (conservative, no evidence of cardiotoxicity at physiologic IGF-1) - DEXA body composition annually **What advanced users should NOT do** - Chase higher and higher IGF-1 ("more is better" mentality) - Stack with exogenous rhGH simultaneously - Combine with other growth-promoting agents (IGF-1 LR3, MGF) — safety envelope breaks - Skip cancer screening ("I feel fine") - Dose above 400 mcg total MOD-GRF 1-29 daily - Continue through any malignancy workup **Consider stopping** - Any new cancer diagnosis - New diabetes with progressive HbA1c elevation - Pregnancy planning - Unexplained organomegaly or acromegaly-like features (very rare at physiologic dosing) - Loss of benefit for 6+ months despite appropriate IGF-1 **Honest assessment** MOD-GRF 1-29 at properly calibrated physiologic doses is one of the better-tolerated GH-axis interventions. It does not replicate exogenous rhGH's dramatic body-composition effects, but it also carries a better safety profile because endogenous feedback remains intact. Long-term (>3 year) data remains limited; users should proceed with consistent monitoring and a willingness to stop. ## Weight-Based Dosing Typically 1–2 mcg/kg per injection. Standard flat dose of 100 mcg is suitable for most individuals. ## Commonly Stacked With **Essential pairing: Ipamorelin** MOD-GRF 1-29 is rarely dosed alone in modern protocols. The canonical stack is: - **MOD-GRF 1-29 100 mcg + Ipamorelin 200 mcg** — single combined SC injection - 1-3 times daily: pre-bed (most important), optional AM fasted, optional pre-workout - Produces 3-5x greater GH pulse than either alone - See Ipamorelin compound page (https://www.bodyhackguide.co/compound/ipamorelin) for pharmacology **Alternative ghrelin-receptor partners** - **Hexarelin 100 mcg** — more potent GH release but raises cortisol and prolactin; not preferred - **MK-677 (ibutamoren) 10-25 mg oral** — daily instead of injection; produces sustained (non-pulsatile) GH; different profile - **GHRP-2 or GHRP-6 100-200 mcg** — older generation; raises appetite (GHRP-6) or has milder profile (GHRP-2) **Recovery and repair pairings** - **BPC-157 250-500 mcg/day SC** — independent tissue healing; no pharmacokinetic conflict. See BPC-157 compound page (https://www.bodyhackguide.co/compound/bpc-157). - **TB-500 / Thymosin beta-4 2-10 mg/week** — tendon/ligament recovery; often stacked for sports injury. **Body composition pairings** - **Tesamorelin (FDA-approved GHRH analog)** — higher potency, prescription-only, FDA-approved for HIV-associated lipodystrophy; not typically stacked with MOD-GRF 1-29 (redundant) - **Testosterone replacement** (clinician-supervised only) — independent anabolic axis; combine with care - **Cardarine (GW-501516) / SR9009** — research chemicals; not recommended due to insufficient long-term safety data **Stacks to avoid** - **CJC-1295 DAC + MOD-GRF 1-29 simultaneously** — redundant GHRH receptor activity; one or the other, not both - **Multiple GHRPs together** (e.g., ipamorelin + hexarelin) — no evidence of benefit, additive side effects - **High-dose exogenous rhGH + secretagogues** — defeats the purpose; use one pathway - **Any GH-raising agent during active malignancy** — IGF-1 concern **Timing with meals** - Administer in **fasted state** (at least 2 hours post-carbohydrate meal) - Postprandial somatostatin tone blunts GH response by 30-70% - Pre-bed dose ideally 2+ hours after last meal - AM dose ideally on waking, before breakfast **Timing with exercise** - Pre-workout dosing (30-60 min before) may amplify training-induced GH response - Post-workout dosing is acceptable but theoretically less optimal (postprandial somatostatin from carb replenishment) **Cycling** - Sermorelin extrapolation suggests **continuous daily use is safe for 6-12 months** with proper monitoring - Some clinicians use **5 days on / 2 days off** to preserve sensitivity - Annual re-assessment of IGF-1 and clinical benefit is appropriate **Related Compounds — Deeper Research Paths** — CJC-1295 (Mod GRF 1-29) is the most-used GHRH analog. Close siblings: CJC-1295 DAC (https://www.bodyhackguide.co/compound/cjc-1295-dac) (longer-acting variant), Sermorelin (https://www.bodyhackguide.co/compound/sermorelin) (older GHRH), Tesamorelin (https://www.bodyhackguide.co/compound/tesamorelin) (visceral-fat specific GHRH). GH secretagogue (GHRP) pairing partners activating the ghrelin receptor: Ipamorelin (https://www.bodyhackguide.co/compound/ipamorelin) (most selective, preferred pair — see CJC-1295 + Ipamorelin blend (https://www.bodyhackguide.co/compound/cjc-ipa-blend)), GHRP-2 (https://www.bodyhackguide.co/compound/ghrp-2), GHRP-6 (https://www.bodyhackguide.co/compound/ghrp-6), Hexarelin (https://www.bodyhackguide.co/compound/hexarelin), MK-677 (https://www.bodyhackguide.co/compound/mk-677) (oral, non-peptide). Downstream effects amplify with IGF-1 LR3 (https://www.bodyhackguide.co/compound/igf-1-lr3). Fat-loss GH stacking: AOD-9604 (https://www.bodyhackguide.co/compound/aod-9604), HGH Fragment 176-191 (https://www.bodyhackguide.co/compound/hgh-frag-176-191). ## Side Effects & Safety **Expected / benign** - **Injection-site reaction** — mild redness, itching, small bump; 24-48 hour resolution - **Facial flushing / warmth** 15-30 min post-injection (histamine release from GHRH action); typically diminishes after week 1-2 - **Mild nausea** in first week at higher doses - **Transient hunger increase** (less than with MK-677 or ghrelin agonists) **Dose-dependent** - **Water retention / mild peripheral edema** — common in first 2-4 weeks, usually resolves - **Tingling or numbness in hands / carpal tunnel symptoms** — dose-related; if persistent, reduce dose - **Morning lethargy or grogginess** — from sub-optimal GH pulse timing; adjust to pre-bed dosing - **Joint stiffness** — particularly in knees and fingers; dose-responsive - **Elevated fasting glucose** — GH is counter-regulatory to insulin; modest at physiologic doses **Uncommon** - **Headache** — usually resolves with dose reduction or improved hydration - **Dizziness or orthostatic hypotension** — rare - **Dream vividness** — common with pre-bed dosing - **Injection-site lipodystrophy** — with repeated same-site injection; rotate sites **Serious (dose- and duration-dependent)** - **Insulin resistance / impaired glucose tolerance** — chronic supraphysiologic GH elevation; rare at proper MOD-GRF 1-29 dosing but more common with DAC variant or MK-677 - **Acromegaly-like features** — not reported at physiologic doses; theoretical at very high chronic dosing - **Potential malignancy risk** — see IGF-1 cancer meta-analysis ([Renehan et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15110491/)). Elevated IGF-1 is epidemiologically associated with increased prostate, colorectal, and premenopausal breast cancer risk - **Carpal tunnel syndrome** — dose-responsive, typically reversible with dose reduction **Absolute contraindications** - Active malignancy (any type) — GH/IGF-1 signaling may promote tumor growth - History of cancer within 5 years — insufficient data to stratify risk - Diabetic retinopathy — IGF-1 promotes retinal neovascularization - Pregnancy and lactation — no safety data - Children with open growth plates — unintended growth acceleration **Relative contraindications** - Type 2 diabetes with poor control (HbA1c >8) — glucose worsening risk - Severe hypothyroidism — suboptimal GH axis function; optimize thyroid first - Intracranial pathology / elevated ICP — theoretical concern - Active autoimmune disease — no direct evidence of harm, but insufficient data **Drug interactions** - **Glucocorticoids** — suppress GHRH response; minimize if possible - **High-dose SSRIs / antipsychotics** — may blunt GH response - **Insulin / insulin secretagogues** — GH raises glucose; monitor **Lab monitoring** - IGF-1 baseline and 8-12 weeks after starting - Fasting glucose and HbA1c quarterly for first year, then annually - Age-appropriate cancer screening per USPSTF guidelines (no different from non-users) Contraindications **Absolute contraindications** - **Active malignancy of any type** — GH/IGF-1 axis stimulation is theoretically pro-tumorigenic; substantive epidemiologic signal for prostate, colorectal, and premenopausal breast cancer ([Renehan et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15110491/)) - **Diabetic retinopathy (active or history)** — IGF-1 promotes retinal neovascularization - **Pregnancy and lactation** — no safety data, GH axis alterations during pregnancy have unknown consequences - **Children with open growth plates** — unintended longitudinal growth - **Critical illness requiring ICU care** — exogenous GH increased mortality in critically ill patients ([Takala et al., 1999, *NEJM*]) **Relative contraindications (clinician-guided)** - History of cancer within 5 years — individualize risk/benefit with oncology - Type 2 diabetes with poor control (HbA1c >8) — GH worsens insulin resistance - Severe hypothyroidism — suboptimal GH response; optimize thyroid first - Intracranial pathology / elevated ICP — theoretical concern with GH - Obstructive sleep apnea — GH may exacerbate upper-airway soft tissue **Drug interactions** - **Glucocorticoids (prednisone, dexamethasone)** — blunt GHRH response; minimize if possible - **Somatostatin analogs (octreotide, lanreotide)** — direct GH suppression; incompatible use - **Insulin and insulin secretagogues** — GH is counter-regulatory; monitor glucose - **Oral estrogens (high-dose)** — blunt hepatic IGF-1 response - **Chemotherapy agents** — avoid concurrent use during active chemo **Surgery and procedure considerations** - Hold for 1-2 weeks before elective major surgery (conservative) - Disclose use to all clinicians, particularly oncology, ophthalmology, endocrinology - Not a concern for routine procedures (dental, dermatologic) **Disclosure obligations** - All clinicians, especially oncology, ophthalmology, endocrinology - Insurance and life-insurance applications (material in some jurisdictions) - Anti-doping: GH-releasing peptides are WADA-prohibited at all times — not appropriate for competitive athletes subject to testing Check interactions with the Interaction Checker → (https://www.bodyhackguide.co/tools/interaction-checker) ## Additional Notes **Standard dose: 100 mcg SC per injection** - Most protocols use **100 mcg per dose** regardless of dose frequency - Increasing per-dose above 100 mcg does not meaningfully increase GH pulse (receptor saturation) but adds side effects - Frequency scales effect: 1x/day < 2x/day < 3x/day **Dose frequency tiers** | Frequency | Use case | IGF-1 elevation | | --- | --- | --- | | 100 mcg pre-bed only | Beginner, sleep-focused | Modest | | 100 mcg AM + PM | Standard protocol | Moderate | | 100 mcg 3x/day | Body composition focus | Maximum physiologic | | 200 mcg single dose | NOT recommended | Receptor-saturated; wasted dose | **Timing with meals** - Fasted state (2+ hours post-carb meal) — essential - Postprandial somatostatin blunts GH pulse by 30-70% - Pre-bed: at least 2 hours after dinner - AM: immediately on waking before any food **Timing with exercise** - Pre-workout (30-60 min before) amplifies training-induced GH - Post-workout less optimal (protein/carb meals raise somatostatin) - If only one dose per day, pre-bed > pre-workout > AM **Injection route** - Subcutaneous only (IM has no pharmacokinetic advantage) - Lower abdomen, thigh, or upper arm; rotate sites - 29-31G insulin needle **Storage** - Lyophilized: -20°C (freezer) ideal; refrigerated (2-8°C) acceptable for short term - Reconstituted: refrigerated 2-8°C; use within 28 days - Do NOT freeze reconstituted solution - Protect from light **What NOT to do** - Do not dose in the morning after breakfast (wasted dose) - Do not exceed 100 mcg per injection (no added benefit, more side effects) - Do not mix with DAC variant in same protocol (redundant) - Do not skip fasting window (severely blunts response) Where to Buy CJC-1295 (Mod GRF 1-29) Compare 6 listings across 4 vendors, from $29.00 https://www.bodyhackguide.co/compound/cjc-1295 ## Frequently Asked Questions What is the recommended CJC-1295 (Mod GRF 1-29) dosage? The typical dose range for CJC-1295 (Mod GRF 1-29) is Without DAC: 100-300 mcg subcutaneous 1-3x daily (typically pre-bedtime); With DAC: 1000-2000 mcg subcutaneous once weekly. It is usually administered 1–3 times daily, typically before bed and/or upon waking. Always start with the lowest effective dose. How often should I take CJC-1295 (Mod GRF 1-29)? Does CJC-1295 (Mod GRF 1-29) need to be cycled? Yes, typical cycle length is 8–16 weeks; can be used long-term with periodic breaks. What are CJC-1295 (Mod GRF 1-29) side effects? Where can I buy CJC-1295 (Mod GRF 1-29)? Compare 6 listings from 4 vendors on our price comparison page, starting from $29.00. CJC-1295 (Mod GRF 1-29) Full Profile Research data, mechanisms, and pricing https://www.bodyhackguide.co/compound/cjc-1295 Interaction Checker Check drug & compound interactions https://www.bodyhackguide.co/tools/interaction-checker ## Related Dosage Guides All Guides (https://www.bodyhackguide.co/guides) ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/cjc-1295-with-dac ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/cjc-1295-dac ### GHRP-2 Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/ghrp-2 ### GHRP-6 Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/ghrp-6 Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Article", "headline": "CJC-1295 Dosage Guide [2026]", "description": "Complete CJC-1295 (Mod GRF 1-29) dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026.", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the recommended CJC-1295 (Mod GRF 1-29) dosage?", "acceptedAnswer": { "@type": "Answer", "text": "The typical dose range for CJC-1295 (Mod GRF 1-29) is Without DAC: 100-300 mcg subcutaneous 1-3x daily (typically pre-bedtime); With DAC: 1000-2000 mcg subcutaneous once weekly. It is usually administered 1–3 times daily, typically before bed and/or upon waking. Always start with the lowest effective dose." } }, { "@type": "Question", "name": "How often should I take CJC-1295 (Mod GRF 1-29)?", "acceptedAnswer": { "@type": "Answer", "text": "1–3 times daily, typically before bed and/or upon waking" } }, { "@type": "Question", "name": "Does CJC-1295 (Mod GRF 1-29) need to be cycled?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, typical cycle length is 8–16 weeks; can be used long-term with periodic breaks." } }, { "@type": "Question", "name": "What are CJC-1295 (Mod GRF 1-29) side effects?", "acceptedAnswer": { "@type": "Answer", "text": "**Expected / benign**\n- **Injection-site reaction** — mild redness, itching, small bump; 24-48 hour resolution\n- **Facial flushing / warmth** 15-30 min post-injection (histamine release from GHRH action); typically diminishes after week 1-2\n- **Mild nausea** in first week at higher doses\n- **Transient hunger increase** (less than with MK-677 or ghrelin agonists)\n\n**Dose-dependent**\n- **Water retention / mild peripheral edema** — common in first 2-4 weeks, usually resolves\n- **Tingling or numbness in hands / carpal tunnel symptoms** — dose-related; if persistent, reduce dose\n- **Morning lethargy or grogginess** — from sub-optimal GH pulse timing; adjust to pre-bed dosing\n- **Joint stiffness** — particularly in knees and fingers; dose-responsive\n- **Elevated fasting glucose** — GH is counter-regulatory to insulin; modest at physiologic doses\n\n**Uncommon**\n- **Headache** — usually resolves with dose reduction or improved hydration\n- **Dizziness or orthostatic hypotension** — rare\n- **Dream vividness** — common with pre-bed dosing\n- **Injection-site lipodystrophy** — with repeated same-site injection; rotate sites\n\n**Serious (dose- and duration-dependent)**\n- **Insulin resistance / impaired glucose tolerance** — chronic supraphysiologic GH elevation; rare at proper MOD-GRF 1-29 dosing but more common with DAC variant or MK-677\n- **Acromegaly-like features** — not reported at physiologic doses; theoretical at very high chronic dosing\n- **Potential malignancy risk** — see IGF-1 cancer meta-analysis ([Renehan et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15110491/)). Elevated IGF-1 is epidemiologically associated with increased prostate, colorectal, and premenopausal breast cancer risk\n- **Carpal tunnel syndrome** — dose-responsive, typically reversible with dose reduction\n\n**Absolute contraindications**\n- Active malignancy (any type) — GH/IGF-1 signaling may promote tumor growth\n- History of cancer within 5 years — insufficient data to stratify risk\n- Diabetic retinopathy — IGF-1 promotes retinal neovascularization\n- Pregnancy and lactation — no safety data\n- Children with open growth plates — unintended growth acceleration\n\n**Relative contraindications**\n- Type 2 diabetes with poor control (HbA1c >8) — glucose worsening risk\n- Severe hypothyroidism — suboptimal GH axis function; optimize thyroid first\n- Intracranial pathology / elevated ICP — theoretical concern\n- Active autoimmune disease — no direct evidence of harm, but insufficient data\n\n**Drug interactions**\n- **Glucocorticoids** — suppress GHRH response; minimize if possible\n- **High-dose SSRIs / antipsychotics** — may blunt GH response\n- **Insulin / insulin secretagogues** — GH raises glucose; monitor\n\n**Lab monitoring**\n- IGF-1 baseline and 8-12 weeks after starting\n- Fasting glucose and HbA1c quarterly for first year, then annually\n- Age-appropriate cancer screening per USPSTF guidelines (no different from non-users)" } }, { "@type": "Question", "name": "Where can I buy CJC-1295 (Mod GRF 1-29)?", "acceptedAnswer": { "@type": "Answer", "text": "Compare 6 listings from 4 vendors on our price comparison page, starting from $29.00." } } ] }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Guides", "item": "https://www.bodyhackguide.co/guides" }, { "@type": "ListItem", "position": 3, "name": "Dosage Guides", "item": "https://www.bodyhackguide.co/guides" }, { "@type": "ListItem", "position": 4, "name": "CJC-1295 (Mod GRF 1-29) Dosage", "item": "https://www.bodyhackguide.co/guides/dosage/cjc-1295" } ] } ] ```